DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / OMX Ventures, LLC
OMX Ventures, LLC
both early and growth/opportunity families, reported GAV $264M
Importance
29
moderate
Active deployment
19
moderate
Emerging
0
low
Completeness
63
high
Freshness
100
high
Research priority
10
low
Identity and regulatory footprint
- Headquarters
- Lincolnshire, ILadviserinfo.sec.gov
- Office address
- ONE OVERLOOK POINT, SUITE 100, Lincolnshire, IL, 60069adviserinfo.sec.gov
- Business phone
- 847-634-2389adviserinfo.sec.gov
- Website
- https://www.omx.vc
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 27, 2026
- Private funds reported
- 2 (2 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $253Madviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- business email
- info@omx.vcomx.vcpublished by the subject
- business phone
- 847-634-2389adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
5 observed deals
Stated (the firm’s website)
- Sectors
- ai, biotech, medtech, climate
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation: no observed deals yet
Stage at first entry: no observed deals yet
Sectors
unknown 100%
lead rate n/afollow-on rate n/anew logos, 12 months 5
Funds and vehicles
2 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| OMX Opportunity Fund I, LLC | Opportunity fund | 2022 adv first reported | Active deployment | $76.6M Mar 27, 2024 | 88 | unknown | unknown |
| OMX Ventures Fund I, LLC | Fund | 2020 form d first sale | Mature | $188M Mar 27, 2024 | 115 | $73.7M of $150M | May 18, 2020 |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
13 current, 1 departed
Natasha Azar
Investor relationsVice President Investor Relations
Anthony Craig Asher
PartnerManaging Director · since Mar 1, 2020
Craig Asher
PartnerManaging Director
Dan Fero
PartnerManaging Director
Daniel James Fero
PartnerManaging Director · since Mar 1, 2020
Nicholas Gabriel Haft
PartnerManaging Director · since Mar 1, 2020
Nick Haft
PartnerManaging Director
John Nawrocki
Platform and operationsChief Financial Officer
John Stanley Nawrocki
Platform and operationsChief Financial Officer · since Mar 1, 2020
Fred Sweeney
Venture partnerVenture Partner
Paul Conley
Venture partnerVenture Partner
Tim Richardson
Venture partnerVenture Partner
Swetha Murali
Vice presidentVice President
1 departed (kept with end dates)
- Paul Alan Conley · Managing Director · Mar 1, 2020 to Mar 30, 2023 Inference
Investments on record
5 edges, 4 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| 10x Genomics · exited | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Ginkgo Bioworks · exited | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Twist Bioscience · exited | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Xeris Biopharma · exited | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Ginkgo Bioworks · exited | portfolio listing | unknown | unknown | unknown | unknown | Sep 13, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
3 relationships from shared deals, counted for the whole firm
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
4 dated events
- Mar 30, 2023Paul Alan Conley (Managing Director) no longer on Schedule A of OMX Ventures, LLC
- Mar 30, 2022OMX Opportunity Fund I, LLC first reported on Form ADV by OMX Ventures, LLC (Venture Capital Fund), GAV $69,470,947Fund first reported on Form ADVFundsFactOMX Opportunity Fund I, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 7, 2021OMX Ventures, LLC first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Apr 7, 2021OMX Ventures Fund I, LLC first reported on Form ADV by OMX Ventures, LLC (Venture Capital Fund), GAV $175,987,078Fund first reported on Form ADVFundsFactOMX Ventures Fund I, LLCSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 12, 2026Multi-stage venture firm (confirmed, 95%, cls-1)both early and growth/opportunity families, reported GAV $264M
Evidence
41 observations from 3 sources